K

Kura Oncology

D
KURA
USD
-0.075
(-0.4208%)
Market Closed
16,814.00
Volume
-2.46
EPS
-
Div Yield
-7.959641
P/E
1,360,262,304.00
Market Cap
Today
-0.4208%
1 Week
6.211%
1 Month
-0.893%
6 Months
-15.745%
12 Months
91.685%
Year To Date
23.350%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
R
RL
14.98
(7.2399%)
USD
U
UAA
2.375
(27.1274%)
USD
V
VFC
0.245
(1.1459%)
USD
NKE
NKE
0.63
(0.8368%)
USD
C
COLM
2.04
(2.4549%)
USD
P
PVH
3.14
(3.0715%)
USD
U
ULTA
5.72
(1.4751%)
USD
G
GPS
(%)
USD
LULU
LULU
2.15
(0.6863%)
USD

Title:
Kura Oncology

Sector:
Healthcare
Industry:
Biotechnology
Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operationof the group is carried through the United States.
Do you need help or have a question?
Contact Us